Sage Therapeutics Inc (SAGE):製薬・医療:M&Aディール及び事業提携情報

GlobalDataが発行した調査報告書(DATA904C9956)
◆英語タイトル:Sage Therapeutics Inc (SAGE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9956
◆発行会社(リサーチ会社):GlobalData
◆発行日:2018年11月
◆ページ数:79
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥26,250見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥52,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥78,750見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
Sage Therapeutics Inc (Sage) is a clinical-stage biopharmaceutical company that discovers and develops therapeutics and medicines for central nervous system (CNS) disorders. It develops drugs based on selective allosteric modulation of CNS synaptic and extrasynaptic receptors. The company has a portfolio of product candidates with the focus of being able to modulate two critical CNS receptor systems, NMDA and GABA. The company’s pipeline products include Brexanolone, SAGE-217, SAGE-324 and SAGE-718 compounds for use in treatment of indications such as postpartum depression, major depressive disorders, bipolar depression, Parkinson’s disease, insomnia, epileptiform disorders and NMDA hypofunction. Sage is headquartered in Cambridge, Massachusetts, the US.

Sage Therapeutics Inc (SAGE) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Sage Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Sage Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Sage Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Sage Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Sage Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Sage Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Sage Therapeutics Raises US$38 Million In Series C Venture Financing 11
Sage Therapeutics Raises US$10 Million In Venture Financing 13
Sage Therapeutics Raises US$20 Million In Series B Venture Financing 14
Sage Therapeutics Raises US$2.8 Million In Expanded Series A Financing Round 15
Partnerships 16
Sage Therapeutics and Shionogi Enter into Co-Development Agreement 16
Licensing Agreements 17
Sage Therapeutics Enters into Licensing Agreement with Ligand Pharma 17
Sage Therapeutics Enters into Licensing Agreement with University of California 18
Sage Therapeutics Enters Into Licensing Agreement With Washington University To Develop Gaba Receptor Small Molecules 19
Sage Therapeutics Amends Licensing Agreement with Regents of the University of California and University of California, Davis 20
Sage Therapeutics Amends Licensing Agreement with CyDex Pharma 21
Equity Offering 22
Sage Therapeutics Raises USD575 Million in Public Offering of Shares 22
Sage Therapeutics Raises USD345 Million in Public Offering of Shares 24
Sage Therapeutics Raises USD201 Million in Public Offering of Shares 26
Sage Therapeutics Raises USD150 Million in Public Offering of Shares 28
Sage Therapeutics Raises USD138 Million in Public Offering of Shares 30
Sage Therapeutics Raises USD103.5 Million in IPO 32
Sage Therapeutics Inc – Key Competitors 34
Sage Therapeutics Inc – Key Employees 35
Sage Therapeutics Inc – Locations And Subsidiaries 36
Head Office 36
Other Locations & Subsidiaries 36
Recent Developments 37
Financial Announcements 37
Aug 07, 2018: Sage therapeutics announces second quarter 2018 financial results and highlights pipeline and business progress 37
May 03, 2018: Sage Therapeutics Announces First Quarter 2018 Financial Results and Provides Update on Pipeline and Progress toward Launch Readiness 39
Feb 22, 2018: Sage Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results 42
Nov 02, 2017: Sage Therapeutics Announces Third Quarter 2017 Financial Results and Provides Pipeline Update 45
Aug 03, 2017: Sage Therapeutics Announces Second Quarter 2017 Financial Results and Provides Pipeline Update 48
May 09, 2017: Sage Therapeutics Announces First Quarter 2017 Financial Results and Provides Pipeline Update 50
Feb 23, 2017: Sage Therapeutics Announces Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update 53
Corporate Communications 56
Nov 08, 2017: Sage Therapeutics Appoints Asha Nayak, M.D., Ph.D., to Board of Directors 56
Jul 10, 2017: Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) 57
Apr 24, 2017: Sage Therapeutics Appoints Michael Cloonan as Chief Business Officer and Expands Executive Team 58
Product News 59
04/19/2017: Sage Therapeutics to Present at American Academy of Neurology 2017 Annual Meeting 59
02/07/2018: Sage Therapeutics Receives FDA Breakthrough Therapy Designation for SAGE-217 for the Treatment of Major Depressive Disorder 60
01/31/2018: Sage Therapeutics Announces Positive Results from Placebo-Controlled Trial in a Model of Insomnia Demonstrating Activity on Sleep Parameters and Supporting Development of SAGE-217 as Potential Treatment for Sleep Disorders 61
Product Approvals 63
May 30, 2018: Sage Therapeutics Announces FDA Acceptance of NDA Filing and Grant of Priority Review for Brexanolone IV in the Treatment of Postpartum Depression 63
Apr 23, 2018: Sage Therapeutics Submits New Drug Application to U.S. FDA for Intravenous Brexanolone in the Treatment of Postpartum Depression 64
May 18, 2017: Sage Therapeutics Receives Fast Track Designation for SAGE-217 for the Treatment of Major Depressive Disorder 65
Clinical Trials 66
Jun 12, 2018: Sage Announces Pivotal Phase 3 Trial Status for SAGE-217 in Major Depressive Disorder and Postpartum Depression based on FDA Breakthrough Therapy Meeting 66
Apr 17, 2018: Sage Therapeutics to Present Brexanolone Postpartum Depression Data at Upcoming Spring Medical Meetings 67
Apr 17, 2018: Sage Therapeutics to Present SAGE-217 Major Depressive Disorder Data at Upcoming Spring Medical Meetings 68
Dec 07, 2017: Sage Therapeutics Reports Positive Top-line Results from Phase 2 Placebo-Controlled Trial of SAGE-217 in Major Depressive Disorder 69
Nov 09, 2017: Sage Therapeutics Announces Brexanolone Achieves Primary Endpoints in Both Phase 3 Clinical Trials in Postpartum Depression 71
Sep 12, 2017: Sage Therapeutics Reports Top-Line Results from Phase 3 STATUS Trial of Brexanolone in Super-Refractory Status Epilepticus 73
Jul 11, 2017: Alzheimer’s Drug Discovery Foundation announces new grant for an innovative Allopregnanolone clinical trial 74
Jun 12, 2017: Sage Therapeutics Announces The Lancet Publishes Positive Phase 2 Brexanolone (SAGE-547) Clinical Data in Severe Postpartum Depression 75
Apr 19, 2017: Sage Therapeutics to Present on SAGE-217 at American Academy of Neurology 2017 Annual Meeting 76
Feb 13, 2017: Sage Therapeutics Advances SAGE-217 into Placebo-Controlled Phase 2 Clinical Trial in Major Depressive Disorder 77
Appendix 79
Methodology 79
About GlobalData 79
Contact Us 79
Disclaimer 79

List of Tables
Sage Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Sage Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Sage Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Sage Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Sage Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Sage Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Sage Therapeutics Raises US$38 Million In Series C Venture Financing 11
Sage Therapeutics Raises US$10 Million In Venture Financing 13
Sage Therapeutics Raises US$20 Million In Series B Venture Financing 14
Sage Therapeutics Raises US$2.8 Million In Expanded Series A Financing Round 15
Sage Therapeutics and Shionogi Enter into Co-Development Agreement 16
Sage Therapeutics Enters into Licensing Agreement with Ligand Pharma 17
Sage Therapeutics Enters into Licensing Agreement with University of California 18
Sage Therapeutics Enters Into Licensing Agreement With Washington University To Develop Gaba Receptor Small Molecules 19
Sage Therapeutics Amends Licensing Agreement with Regents of the University of California and University of California, Davis 20
Sage Therapeutics Amends Licensing Agreement with CyDex Pharma 21
Sage Therapeutics Raises USD575 Million in Public Offering of Shares 22
Sage Therapeutics Raises USD345 Million in Public Offering of Shares 24
Sage Therapeutics Raises USD201 Million in Public Offering of Shares 26
Sage Therapeutics Raises USD150 Million in Public Offering of Shares 28
Sage Therapeutics Raises USD138 Million in Public Offering of Shares 30
Sage Therapeutics Raises USD103.5 Million in IPO 32
Sage Therapeutics Inc, Key Competitors 34
Sage Therapeutics Inc, Key Employees 35
Sage Therapeutics Inc, Subsidiaries 36

List of Figures
Sage Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Sage Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Sage Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Sage Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Sage Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Sage Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Sage Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Sage Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ Sage Therapeutics Inc (SAGE):製薬・医療:M&Aディール及び事業提携情報(Sage Therapeutics Inc (SAGE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆